William Blair Has Positive Estimate for Hologic Q3 Earnings

Hologic, Inc. (NASDAQ:HOLX) – Equities researchers at William Blair raised their Q3 2025 earnings estimates for shares of Hologic in a research note issued to investors on Thursday, February 6th. William Blair analyst A. Brackmann now anticipates that the medical equipment provider will post earnings per share of $1.12 for the quarter, up from their prior estimate of $1.10. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. William Blair also issued estimates for Hologic’s Q4 2025 earnings at $1.10 EPS, Q1 2026 earnings at $1.11 EPS, Q2 2026 earnings at $1.10 EPS, Q3 2026 earnings at $1.17 EPS, Q4 2026 earnings at $1.17 EPS and FY2026 earnings at $4.55 EPS.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%.

Several other equities research analysts also recently weighed in on HOLX. Wolfe Research started coverage on Hologic in a report on Friday, December 13th. They issued a “peer perform” rating for the company. Royal Bank of Canada lowered their target price on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research note on Thursday. Leerink Partnrs cut shares of Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday. Leerink Partners downgraded shares of Hologic from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $80.00 to $75.00 in a research note on Thursday. Finally, JPMorgan Chase & Co. upped their target price on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Ten research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic presently has an average rating of “Moderate Buy” and a consensus target price of $85.77.

Hologic Stock Down 1.3 %

Hologic stock opened at $64.58 on Friday. Hologic has a 1-year low of $63.88 and a 1-year high of $84.67. The business has a fifty day moving average price of $72.33 and a 200-day moving average price of $77.76. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The stock has a market capitalization of $14.58 billion, a price-to-earnings ratio of 19.39, a PEG ratio of 2.35 and a beta of 0.98.

Insiders Place Their Bets

In related news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.88% of the company’s stock.

Institutional Investors Weigh In On Hologic

A number of institutional investors have recently added to or reduced their stakes in the stock. Wolff Wiese Magana LLC purchased a new position in shares of Hologic in the third quarter valued at approximately $25,000. General Partner Inc. purchased a new position in shares of Hologic during the 4th quarter worth $26,000. Venturi Wealth Management LLC raised its holdings in Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares during the period. First Horizon Advisors Inc. lifted its position in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the last quarter. Finally, Cromwell Holdings LLC boosted its stake in Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 416 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.